(223)RaCl2
(223)racl2
A radium molecular entity with formula <small><sup>223</small></sup>RaCl<small><sub>2</sub></small>. Used as as a radiotherapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. An alpha-emitter, radium-223 has a half-life of 11.4 days.